Transcatheter aortic valve replacement (TAVR) has revolutionized the management of aortic stenosis (AS). When Dr. Andersen envisioned the replacement of the aortic valve through a balloon-facilitated method, many of the factors associated with it were undoubtedly not anticipated . Disruptive technology fairly arrives with disruptive factors. It was a novel idea that has proven to be successful since the first procedure by Dr. Alain Cribier . Prior to transcatheter aortic valve replacement, approximately 40% of patients with severe symptomatic aortic stenosis were undertreated . With improvement in technology, TAVR has evolved to become the standard of care for treatment of severe aortic stenosis, regardless of the patient's risk score. This is based on rigorous clinical trials and approved by the Food and Drug Administration (FDA) in the United States and accepted worldwide .